PHAXIAM Therapeutics S.A. (0QSS.L)

2,9246 -0,0687 (-2,30%) In data: 05:52PM BST. Mercato aperto.

PHAXIAM Therapeutics S.A.

60 Avenue Rockefeller
Bâtiment Adénine
Lyon 69008
France
33 4 78 74 44 38
https://www.phaxiam.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 68

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Eric Soyer Ph.D.	Deputy CEO, Deputy GM, CFO & COO	379,72k	N/D	1966
Dr. Jérôme Bailly Pharm.D.	Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person	247,91k	N/D	1979
Mr. Thibaut du Fayet	Chief Executive Officer	N/D	N/D	1968
Ms. Céline Breda	Chief Technology Officer	N/D	N/D	1971
Ms. Cindy Fevre	Chief Scientific Officer	N/D	N/D	N/D
Naomi Eichenbaum	Director Investor Relations	N/D	N/D	N/D
Ms. Anne-Cécile Fumey	Vice President of Human Resources	N/D	N/D	1976
Ms. Karine Charton Ph.D.	Chief Business Officer	N/D	N/D	N/D
Dr. Pascal Birman M.D.	Chief Medical Officer	N/D	N/D	N/D
Ms. Frederique Vieville	Chief Regulatory Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Governance aziendale

L'ISS Governance QualityScore di PHAXIAM Therapeutics S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.